A new trading day began on Friday, with Janux Therapeutics Inc (NASDAQ: JANX) stock price up 4.34% from the previous day of trading, before settling in for the closing price of $23.27. JANX’s price has ranged from $22.48 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.33% over the past five years. Meanwhile, its annual earnings per share averaged -54.46%. With a float of $49.57 million, this company’s outstanding shares have now reached $59.17 million.
Let’s look at the performance matrix of the company that is accounted for 81 employees. In terms of profitability, gross margin is 94.58%, operating margin of -1216.61%, and the pretax margin is -832.71%.
Janux Therapeutics Inc (JANX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 16.13%, while institutional ownership is 110.39%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -54.46% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Here are Janux Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 58.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 153.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (NASDAQ: JANX) saw its 5-day average volume 1.38 million, a positive change from its year-to-date volume of 1.01 million. As of the previous 9 days, the stock’s Stochastic %D was 11.54%. Additionally, its Average True Range was 2.17.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 4.60%, which indicates a significant decrease from 15.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.41% in the past 14 days, which was higher than the 71.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.85, while its 200-day Moving Average is $42.30. Nevertheless, the first resistance level for the watch stands at $24.68 in the near term. At $25.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.70. If the price goes on to break the first support level at $23.66, it is likely to go to the next support level at $23.04. The third support level lies at $22.64 if the price breaches the second support level.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
With a market capitalization of 1.44 billion, the company has a total of 59,175K Shares Outstanding. Currently, annual sales are 10,590 K while annual income is -68,990 K. The company’s previous quarter sales were 0 K while its latest quarter income was -20,220 K.
